$3.6M Hemispherx Securities Settlement Gets Final OK

Law360, New York (February 15, 2011, 2:31 PM EST) -- A federal judge has given final approval to a $3.6 million settlement between Hemispherx Biopharma Inc. and a class of plaintiffs who alleged the company misled investors on the approval status of chronic fatigue syndrome drug Ampligen.

Judge Paul S. Diamond of the U.S. District Court for the Eastern District of Pennsylvania gave the final go-ahead for the settlement in the consolidated class action Monday. The class includes all investors who purchased Hemispherx stock between Feb. 18, 2009, and Dec. 1, 2009.

The consolidated class action...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

REID v. HEMISPHERX BIOPHARMA, INC. et al


Case Number

2:09-cv-05262

Court

Pennsylvania Eastern

Nature of Suit

Other Statutes: Securities/Commodities

Judge

PAUL S. DIAMOND

Date Filed

November 10, 2009

Law Firms

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.